CAM
ITCI

Cresset Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Cresset Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,542
Closed -$259K – 2268
2024
Q3 		$259K Sell
3,542
-33
-0.9% -$2.48K ﹤0.01% 1867
2024
Q2 		$245K Sell
3,575
-96
-3% -$6.66K ﹤0.01% 1807
2024
Q1 		$254K Buy
3,671
+86
+2% +$5.91K ﹤0.01% 1661
2023
Q4 		$257K Sell
3,585
-258
-7% -$14.8K ﹤0.01% 1568
2023
Q3 		$200K Buy
+3,843
New +$224K ﹤0.01% 1629

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Cresset Asset Management's ITCI Position: Q4 2024 in Review

Cresset Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2024, closing a stake of 3,542 shares — an estimated $259K sold.

Cresset Asset Management first reported a position in ITCI in Q3 2023 and held it in 5 quarters. The position peaked at $259K in Q3 2024. 387 funds tracked by Wall St. Rank hold ITCI as of Q4 2024.

  • Cresset Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2024 after selling out during the quarter.
  • Cresset Asset Management sold 3,542 Intra-Cellular Therapies Inc. shares in Q4 2024, an estimated $259K.
  • Cresset Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2023 and held it in 5 quarters.
  • Cresset Asset Management's Intra-Cellular Therapies Inc. position peaked at $259K in Q3 2024.
  • 387 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.